GSK PLC Sponsored ADR (GSK)
(Delayed Data from NYSE)
$39.86 USD
+0.79 (2.02%)
Updated Jul 26, 2024 04:00 PM ET
Pre-Market: $40.07 +0.21 (0.53%) 9:26 AM ET
3-Hold of 5 3
A Value C Growth D Momentum B VGM
GSK (GSK) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$46.14 | $53.00 | $38.70 | 15.76% |
Price Target
Based on short-term price targets offered by five analysts, the average price target for GSK comes to $46.14. The forecasts range from a low of $38.70 to a high of $53.00. The average price target represents an increase of 15.76% from the last closing price of $39.86.
Analyst Price Targets (5 )
Broker Rating
GSK currently has an average brokerage recommendation (ABR) of 2.55 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 11 brokerage firms. The current ABR compares to an ABR of 2.73 a month ago based on 11 recommendations.
Of the 11 recommendations deriving the current ABR, four are Strong Buy, representing 36.36% of all recommendations. A month ago, Strong Buy represented 36.36%.
Broker Rating Breakdown
![Broker Rating Visualization](https://widget3.zacks.com/images/charts/bar/brokerage/bar/GSK.png)
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 4 | 4 | 4 | 3 | 3 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 5 | 5 | 4 | 4 | 3 |
Sell | 1 | 1 | 1 | 2 | 2 |
Strong Sell | 1 | 1 | 2 | 2 | 2 |
ABR | 2.55 | 2.55 | 2.73 | 3.00 | 3.00 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
7/8/2024 | UBS | Alexandra M Hauber | Strong Sell | Hold |
7/2/2024 | Cowen & Co. | Steve M Scala | Hold | Hold |
6/24/2024 | Not Identified | Not Identified | Not Available | Strong Buy |
6/20/2024 | Berenberg Bank | Kerry Holford | Not Available | Strong Buy |
5/30/2024 | Goldman Sachs | Rajan Sharma | Not Available | Hold |
5/12/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
5/1/2024 | Not Identified | Not Identified | Hold | Hold |
3/4/2024 | Guggenheim Securities | Seamus Fernandez | Not Available | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 2.55 |
ABR (Last week) | 2.55 |
# of Recs in ABR | 11 |
Average Target Price | $46.14 |
LT Growth Rate | 7.10% |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 81 of 252 |
Current Quarter EPS Est: | 1.00 |